Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 4Leukemia, Promyelocytic, Acute 1

Interventions

Arsenic Trioxide 4Tretinoin 2vadastuximab talirine 1tamibarotene 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cytarabine 1Clofarabine 1AEG 35156 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Promyelocytic, Acute × vadastuximab talirine × Clear all
NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed
195 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡